Lineage Cell Therapeutics Files Q3 2024 10-Q

TL;DR

Lineage Cell Therapeutics filed their Q3 10-Q, showing R&D spend and ATM activity. Keep an eye on burn rate.

AI Summary

Lineage Cell Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported research and development expenses for the third quarter of 2023 and the first nine months of 2024. They also disclosed information regarding their "At-The-Market" (ATM) sales agreement and related equity incentive plans.

Why It Matters

This filing provides investors with an update on Lineage Cell Therapeutics' financial performance and operational activities, including R&D spending and equity financing, crucial for understanding the company's progress and future prospects.

Risk Assessment

Risk Level: medium — Biotech companies like Lineage Cell Therapeutics often carry medium risk due to the inherent uncertainties in drug development and regulatory approvals.

Key Numbers

• N/A — Revenue (Specific revenue figures for the quarter were not explicitly detailed in the provided snippet.)
• N/A — Net Income/Loss (Specific net income or loss figures were not explicitly detailed in the provided snippet.)
• N/A — Cash and Cash Equivalents (While mentioned, a specific dollar amount for cash and cash equivalents as of 2024-09-30 was not provided in the snippet.)

Key Players & Entities

• Lineage Cell Therapeutics, Inc. (company) — Filer of the 10-Q
• 2024-09-30 (date) — End of reporting period
• 2023-07-01 2023-09-30 (date) — Period for R&D expenses
• 2024-01-01 2024-09-30 (date) — Period for R&D expenses and equity incentive plan activity

FAQ

Filing Documents

• lctx-20240930.htm (10-Q) — 2024KB
• lctx-ex31_1.htm (EX-31.1) — 14KB
• lctx-ex31_2.htm (EX-31.2) — 13KB
• lctx-ex32_1.htm (EX-32.1) — 10KB
• 0000950170-24-127077.txt ( ) — 8741KB
• lctx-20240930.xsd (EX-101.SCH) — 1263KB
• lctx-20240930_htm.xml (XML) — 1530KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 5 Condensed Consolidated Balance Sheets 5 Condensed Consolidated Statements of Operations 6 Condensed Consolidated Statements of Comprehensive Loss 7 Condensed Consolidated Statements of Changes in Shareholders' Equity 8 Condensed Consolidated Statements of Cash Flows 10 Notes to the Condensed Consolidated Interim Financial Statements 11 Item 2.

Management's Discussion and Analysis of Financial Condition and Result of Operations

Management's Discussion and Analysis of Financial Condition and Result of Operations 30 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 38 Item 4.

Controls and Procedures

Controls and Procedures 38 PART II. OTHER INFORMATION 39 Item 1.

Legal Proceedings

Legal Proceedings 39 Item 1A.

Risk Factors

Risk Factors 39 Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities 39 Item 3. Defaults Upon Senior Securities 39 Item 4. Mine Safety Disclosures 39 Item 5. Other Information 39 Item 6. Exhibits 40

Signatures

Signatures 41 2 SPECI AL NOTE REGARDING FORWARD-LOOKING STATEMENTS This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), that involve substantial risks and uncertainties. The forward-looking statements are contained principally in Part I, Item 2. "Management's Discussion and Analysis of Financial Condition and Results of Operations" of this report, but are also contained elsewhere in this report. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this report are forward-looking statements. In some cases, you can identify forward-looking statements by the words "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements in this report include, but are not limited to, statements about: the potential to receive developmental, regulatory, and commercialization milestone and royalty payments under our Collaboration and License Agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc.; our plans to research, develop and commercialize our product candidates; the initiation, progress, success, cost and timing of our clinical trials and other product development activities; the therapeutic potential of our product candidates, and the indications for which we intend to develop our product candidates; our ability to successfully manufacture our product candidates for clinical development and, if approved, for commercialization, and the timing and c

View Full Filing

View this 10-Q filing on SEC EDGAR